Biogen Secures China Rights for Felzartamab in $850 Million Deal
Biogen has entered into an agreement with its Chinese partner, TJ Biopharma, to acquire full commercial rights for felzartamab in China for a total of $850 million. The deal includes an upfront payment of $100 million, potential milestone payments of $750 million based on future commercial success, and tiered royalties ranging from the mid-teens to the low twenties. Biogen had previously acquired global rights, excluding China, for felzartamab through the acquisition of HIBio in 2024 for $1.15 billion. This transaction consolidates global development and commercialization rights. This can be interpreted as a typical portfolio optimization strategy where global biopharma companies actively acquire remaining rights from Asian local partners to establish a single decision-making system for their pipelines.
Felzartamab is a monoclonal antibody targeting the CD38 protein found on plasma cells and NK cells, which are involved in the abnormal immune responses. It is being developed for the treatment of IgA Nephropathy (IgAN), Membranous Nephropathy (PMN), and antibody-mediated rejection (AMR) in kidney transplant recipients. The drug has received Breakthrough Therapy designation from the FDA for kidney transplant rejection and membranous nephropathy, demonstrating its clinical potential. It aims to overcome the severe side effects associated with conventional immunosuppressive therapies and provide a targeted treatment option that can preserve kidney function.
China is one of the countries with the highest prevalence of IgAN and PMN. IgA nephropathy is a leading cause of end-stage renal disease (ESRD) in young adults. TJ Biopharma had already submitted a Biologics License Application (BLA) for felzartamab for the treatment of multiple myeloma to the NMPA in 2024, and it is currently under review. With this agreement, Biogen will directly manage the manufacturing and commercialization of felzartamab in China, enabling faster entry into Phase 3 trials and a more efficient supply chain. By taking control of the development in the Chinese market, which has a large patient pool, Biogen aims to maximize global commercial synergies.
The CD38-targeted antibody market is dominated by daratumumab (Daratumumab, brand name Darzalex) from Johnson & Johnson and isatuximab (Isatuximab, brand name Sarclisa) from Sanofi, both of which are used in the treatment of multiple myeloma. However, Biogen is focusing on rare autoimmune kidney diseases, an area with high unmet medical needs, to gain market share. Analysts predict that felzartamab could generate approximately $776 million in global sales by 2032, driven by its strong position in the rare disease market. By focusing on kidney diseases and transplant rejection while competitors focus on oncology, Biogen aims to establish felzartamab as a standard of care and diversify its portfolio.
Biogen's acquisition of full commercial rights for felzartamab in China for $850 million, including a $100 million upfront payment, solidifies its position in the autoimmune and kidney disease pipeline, differentiating it from existing CD38 competitors like daratumumab, which are primarily focused on oncology. In the short to medium term, this will likely accelerate the approval process for the multiple myeloma indication, for which the BLA has already been submitted to the NMPA, and expedite the commercialization of felzartamab in Asia for indications in Phase 3 trials, such as IgAN and PMN. In the long term, this will accelerate the achievement of felzartamab's projected global peak sales of $776 million by 2032 and improve profit margins by directly controlling the Chinese market, which has the largest patient population in Asia, thereby eliminating royalty payments. For researchers and developers, this strategic move facilitates the acquisition of clinical data for innovative therapies targeting multiple indications, thereby strengthening the roadmap for the development of new drugs based on the mechanism of immune-modulating antibody depletion.